KINNATE BIOPHARMA INC.
CIK 0001797768
Revenue (TTM)
—
FY Mar 2024
Net Income (TTM)
−$109.41M
+3.1% YoY
FY Mar 2024
EPS Diluted (TTM)
−$2.76
+8.3% YoY
FY Mar 2024
Gross Margin
—
FY Mar 2024
Operating Margin
—
FY Mar 2024
Net Margin
—
FY Mar 2024
Free Cash Flow (TTM)
−$66.98M
FY Mar 2024
Cash
$57M
FY Mar 2024
Total Debt
—
FY Mar 2024
Shares Outstanding
47.23M sh
FY Mar 2024
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.